Liability for costs due to patient's death if proximately caused by individualized investigational treatment

If a patient’s death is proximately caused by treatment with an individualized investigational drug, biological product, or device, the patient’s estate, heirs, or devisees are not liable for any debt remaining after payment by insurance for charges directly incurred for said treatment. However, this provision does not provide an exemption to liability for charges for non-experimental treatments provided to the patient, including non-experimental treatments rendered to the patient due to complications or consequences of the experimental treatment.